Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through three segments: Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products. The Life Science Services and Products segment provides products and services in various categories, including gene synthesis, oligonucleotide synthesis, peptide synthesis, protein engineering, antibody development, and life-science equipment and consumables, such as molecular diagnostics tools and genome editing materials for biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and the food industry. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People’s Republic of China.